Market Access News | pharmaphorum

News

FDA rejects Citius' revived IL-2 therapy for lymphoma

The FDA has rejected Citius Pharmaceuticals' marketing application for Lymphir, an updated version of a lymphoma therapy withdrawn from sale several years ago.

Home

1000Farmacie Secures $25 Million in Series A Funding

The Healthware Ventures portfolio company 1000Farmacie, a leading Italian e-pharmacy marketplace, has announced the successful completion of its second tranche of Series A

News

Soliris becomes first drug for paediatric gMG in Europe

AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in

News

NICE won't budge on rejection of rare disease drug

The UK's cost-effectiveness agency NICE has delivered its final verdict on Clinuvel's Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to lig

News

Tarsus gets first FDA nod for mite blepharitis therapy

A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<

News

EMA panel rejects Mirati’s KRAS drug Krazati

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the

FDA rejects Citius' revived IL-2 therapy for lymphoma

1000Farmacie Secures $25 Million in Series A Funding

Soliris becomes first drug for paediatric gMG in Europe

NICE won't budge on rejection of rare disease drug

Tarsus gets first FDA nod for mite blepharitis therapy

EMA panel rejects Mirati’s KRAS drug Krazati

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks